Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a registry record of a recruiting interventional study with no reported results; primary outcomes measure feasibility and adherence, not clinical efficacy.
This is a Phase 2, single-arm feasibility study with no results yet posted; it is designed to evaluate concurrent SBRT and immunotherapy but carries no outcome data to assess efficacy or safety.
This is a Phase 2 proof-of-concept study registration with no results reported; the trial is actively recruiting and designed to explore HER3-DXd monotherapy across multiple solid tumor types.
Modelling study based on a single trial's survival data, assessing cost-effectiveness in a specific healthcare system; does not itself evaluate clinical outcomes and depends on external trial evidence and assumptions.
A rigorous health economic analysis based on a pivotal Phase 3 RCT (KEYNOTE-689) with clear cost-effectiveness results well below the Swiss willingness-to-pay threshold, though grounded in modelling rather than direct trial cost outcomes.
Cross-sectional mediation analysis generating associations between dermatitis, mood, and social integration; design cannot establish causality and authors explicitly state findings are hypothesis-generating.
This is a systematic review of 33 observational and experimental studies with no randomized controlled trials or clinical outcome data, synthesizing preclinical and correlative evidence that MTDH is overexpressed in HNC and promotes oncogenic functions, but lacking direct evidence of clinical benefit from MTDH-directed intervention.